The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes

Abstract

Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D6. Methods. The antidepressive medication which the patients were resistant to was kept unchanged during the five weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received sham T-PEMF. The effect size was 1.02 and 0.90, respectively, on HAM-D6 and HAM-D6-S. Concerning side effects, the active T-PEMF reduced the baseline score on concentration problems with an effect size of 0.44 while inducing more autonomic symptoms than sham T-PEMF with an effect size of −0.41. The advantage of active over sham T-PEMF obtained an effect size of 0.48. Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size level above 0.40.

The Effect of Daily Self-Measurement of Pressure Pain Sensitivity Followed by Acupressure on Depression and Quality of Life versus Treatment as Usual in Ischemic Heart Disease: A Randomized Clinical Trial

“…Thus our findings point to a greater effect of our intervention among more psychologically vulnerable subjects. These data on effect size should be compared to the effect size of antidepressants found in placebo-controlled clinical trials of treatment resistant patients with overt depression of approximately 0.40, although our patients did not have overt depression [29]. Further, a meta-analysis on exercise training, a well-known and beneficial treatment, on depressive symptoms among patients with a chronic illness, demonstrated an effect size of 0.30 in patients with mild-to-moderate depression [30].…”

The Performance of the Revised Major Depression Inventory for Self-Reported Severity of Depression - Implications for the DSM-5 and ICD-11

“…The HAM-D 17 uses a time frame (window) of 1 week. In a previous study [10], covering a trial with treatment-resistant typical DSM-IV major depression, we modified the MDI time frame from 2 weeks to the past week. When reanalyzing all observations from this study, the total MDI score had an acceptable convergence with HAM-D 17 using the NICE standardization.…”

Do not blame the SSRIs: blame the Hamilton Depression Rating Scale

“…Notably, none of these three problematic items are included in the HDRS 6 . As the wanted effect (antidepressant effect in this context) and unwanted effects (side effects) are ideally evaluated independently in clinical studies (21)(22)(23), the HDRS 6 is an ideal measure of the wanted effects of antidepressant agents (21,24).…”